Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.58 |
| ▸ | MAG | P20916 | 6/20 | 0.54 |
| ▸ | SELL | P14151 | 2/20 | 0.52 |
| ▸ | SELP | P16109 | 2/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | SELE | P16581 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849014 | 0.97 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPCETP | |
| SCHEMBL29380203 | 0.93 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL12313946 | 0.93 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29699102 | 0.91 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL195718 | 0.91 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL22969674 | 0.91 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30649466 | 0.91 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL20971391 | 0.91 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31126371 | 0.91 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30655036 | 0.91 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260133202-A1 | QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID | JCR PHARMACEUTICALS CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| US-20260133202-A1 | QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID | JCR PHARMACEUTICALS CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| US-20260133202-A1 | QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID | JCR PHARMACEUTICALS CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4019958-B1 | QUANTIFICATION METHOD OF HEX4, LYSO-GM1, FUC-GLCNAC-ASN, AND LYSO-SULFATAIDE INCLUDED IN CEREBROSPINAL FLUID | JAPAN CHEM RES (JP) | 2025-09-24 | — | — | EP | disclosed |
| EP-4019958-B1 | QUANTIFICATION METHOD OF HEX4, LYSO-GM1, FUC-GLCNAC-ASN, AND LYSO-SULFATAIDE INCLUDED IN CEREBROSPINAL FLUID | JAPAN CHEM RES (JP) | 2025-09-24 | — | — | EP | disclosed |
| US-20250289844-A1 | TREATMENT OF GM1 DEFICIENCIES | SENEB BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12383606-B2 | Short chain ceramide-based lipids and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| CN-119971619-A | Synthesis system and synthesis process of monosialotetrahexosyl ganglioside GM1 | 武汉糖智药业有限公司 | 2025-05-13 | — | — | CN | disclosed |
| JP-2025023272-A | METHOD FOR DETERMINING QUANTITY OF Hex4, lyso-GM1, Fuc-GlcNAc-Asn, and LYSO-SULFATIDE IN CEREBROSPINAL FLUID | ＪＣＲファーマ株式会社 | 2025-02-14 | — | — | JP | disclosed |
| JP-7599867-B2 | — | ＪＣＲファーマ株式会社 | 2024-12-16 | — | — | JP | disclosed |
| US-11633467-B2 | Immunogenic composition and vaccine for generating an immune response to norovirus | ICON GENETICS GMBH (DE) | 2023-04-25 | — | — | US | disclosed |
| US-11559568-B2 | Short chain ceramide-based lipids and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| WO-2022153957-A1 | NUCLEIC ACID MOLECULE CONTAINING INCORPORATED GENE ENCODING FUSED PROTEIN OF LIGAND AND PROTEIN HAVING PHYSIOLOGICAL ACTIVITY | ＪＣＲファーマ株式会社 | 2022-07-21 | — | — | WO | disclosed |
| EP-4019958-A1 | QUANTIFICATION METHOD OF HEX4, LYSO-GM1, FUC-GLCNAC-ASN, AND LYSO-SULFATAIDE INCLUDED IN CEREBROSPINAL FLUID | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019958-A1 | QUANTIFICATION METHOD OF HEX4, LYSO-GM1, FUC-GLCNAC-ASN, AND LYSO-SULFATAIDE INCLUDED IN CEREBROSPINAL FLUID | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019958-A1 | QUANTIFICATION METHOD OF HEX4, LYSO-GM1, FUC-GLCNAC-ASN, AND LYSO-SULFATAIDE INCLUDED IN CEREBROSPINAL FLUID | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220178937-A1 | QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID | JCR PHARMACEUTICALS CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220178937-A1 | QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID | JCR PHARMACEUTICALS CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220178937-A1 | QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID | JCR PHARMACEUTICALS CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-11253589-B2 | Modulation of the immune response | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260133202-A1 | QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID | GALC, NEU4, MAN2B1 | SIGLEC7 59/4885MAG 131/4885SELL 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.